Pure Erythroid Leukemia and Erythroblastic Sarcoma Evolving From Chronic Myeloid Neoplasms. Am J Clin Pathol 2016 Apr;145(4):538-51
Date
04/29/2016Pubmed ID
27124944DOI
10.1093/ajcp/aqw033Scopus ID
2-s2.0-84981272203 (requires institutional sign-in at Scopus site) 27 CitationsAbstract
OBJECTIVES: Pure erythroid leukemia (PEL) is an extremely rare entity that may, even more rarely, evolve from a preexisting chronic myeloid neoplasm (CMN); there is minimal literature regarding this latter phenomenon.
METHODS: We describe 14 patients with PEL that represented progression from a preexisting myelodysplastic syndrome (MDS, nā=ā8) or myeloproliferative neoplasm (MPN, nā=ā6), three of which manifested as erythroblastic sarcoma (EBS), a rare entity. These patients had a highly complex karyotype with prominent clonal evolution and a very aggressive clinical course.
RESULTS: Patients with PEL from MDS showed a more rapid progression time to PEL and had lower platelet counts compared with PEL from MPN. No other significant differences were found between the two groups.
CONCLUSIONS: These data represent the largest cohort of patients with PEL and an antecedent CMN, as well as the largest series of EBS reported to date, and underscore the unique morphologic, cytogenetic, immunophenotypic, and clinical features of this uncommon entity.
Author List
Li H, Hasserjian RP, Kroft SH, Harrington AM, Wheaton SE, Pildain A, Ewalt MD, Gratzinger D, Hosking P, Olteanu HAuthors
Alexandra M. Harrington MD Professor in the Pathology department at Medical College of WisconsinSteven Howard Kroft MD Chair, Professor in the Pathology department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdultAged
Disease Progression
Female
Flow Cytometry
Humans
Immunohistochemistry
Leukemia, Erythroblastic, Acute
Male
Middle Aged
Myeloproliferative Disorders